HIGHLIGHTS
- who: Sebastian Hörner and colleagues from the Department of Immunology, Institute for Cell Biology, Eberhard Karls University Tuebingen, German Cancer Consortium (DKTK), Partner Site Tuebingen, Tuebingen, Germany have published the article: IgG-Based Bispecific Anti-CD95 Antibodies for the Treatment of B Cell-Derived Malignancies and Autoimmune Diseases, in the Journal: Cancers 2022, 14, 3941. of /2022/
- what: Bispecific anti-CD95 antibodies are promising candidates for a more specific depletion of malignant and autoreactive B cells and hold promise to improve the safety and efficacy compared to previously established antibody therapies.
- how . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.